Edgar Filing: Chawla Lakhmir S - Form 4

Form 4	imir S										
October 15, 2	2018										
FORM	4								OMB AF	PPROVAL	
	UNITEI) STATES		AITIES A			NGE C	COMMISSION	OMB Number:	3235-0287	
Check thi if no long subject to Section 1 Form 4 of	6. STATE	STATEMENT OF CHANC				GES IN BENEFICIAL OWNERSHIP SECURITIES				January 31, 2005 Iverage rs per 0.5	
may conti	obligations may continue. See Instruction See						response				
(Print or Type R	Responses)										
1. Name and Address of Reporting Person <u>*</u> Chawla Lakhmir S			2. Issuer Name and Ticker or Trading Symbol LA JOLLA PHARMACEUTICAL CO [LJPC]				-	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) C/O LA JOI PHARMAC COMPANY CENTRE C	EUTICAL 7,, 4550 TOWN	(Middle) E	3. Date of (Month/D 10/15/20		ansaction			Director X Officer (give below) Chief		Owner er (specify er	
	(Street)	(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person 					
SAN DIEGO	D, CA 92121							Form filed by M Person			
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative	Secur	ities Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Da (Month/Day/Yea	r) Executio any	ned n Date, if Day/Year)	3. Transactio Code (Instr. 8) Code V	4. Securit r(A) or Di (Instr. 3, Amount	spose	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock	10/15/2018			A <u>(1)</u>	15	A	\$ 13.81	2,100	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: Chawla Lakhmir S - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	a 3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		(Instr. 3 and 4)		8. Price Deriva Securit (Instr. :
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 16.25	10/15/2018		А	15	(2)	10/15/2028	Common Stock	15	\$ (

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Chawla Lakhmir S C/O LA JOLLA PHARMACEUTICAL COMPANY, 4550 TOWNE CENTRE COURT SAN DIEGO, CA 92121			Chief Medical Officer			
Signatures						
/s/ Ryan Murr, as attorney-in-fact for Lakhmir S. Chawla	10/15	/2018				
**Signature of Reporting Person	Da	te				

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These shares were acquired on 10/15/2018 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- (2) The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.